German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up investment in a promising new medical area to revive its drug development pipeline.
Source:: Reuters – Business News
Newswire
- [ January 15, 2025 ] Vision Marine Technologies (NASDAQ:VMAR) Files Patent Application for Proprietary Battery Encryption System Newsmakers
- [ January 15, 2025 ] Safe & Green Holdings (NASDAQ: SGBX)Announces LOI for Transformative Acquisition of Olenox and Machfu.com Newsmakers
- [ January 14, 2025 ] Castellum (NYSE: CTM) Announces the Award of a $3.2 million Contract to its Specialty Systems, Inc. Subsidiary Newsmakers
- [ January 14, 2025 ] Richtech Robotics (NASDAQ: RR) to Showcase Latest Service Robotics Innovations at CES 2025, Featuring AI-Driven Scorpion Robot and New Delivery Robots Newsmakers
- [ January 14, 2025 ] Firefly Neuroscience (NASDAQ: AIFF) Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform Newsmakers
- [ January 14, 2025 ] Nature’s Miracle Holding, Inc. (NASDAQ: NMHI) Announces Up to $29.7 Million Financing Newsmakers
- [ January 14, 2025 ] Eterna Therapeutics (NASDAQ: ERNA) Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer Newsmakers
- [ January 13, 2025 ] Phio Pharmaceuticals (NASDAQ: PHIO) Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762 Newsmakers
- [ January 13, 2025 ] Helius (NASDAQ:HSDT) Announces First Portable Neuromodulation Stimulator (PoNS®) System Sale to the Veterans Affairs (VA) Healthcare System Newsmakers
- [ January 7, 2025 ] Immuneering (NASDAQ: IMRX) Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms Newsmakers
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.